These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36778025)

  • 21. Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor.
    Gómez-Ganda L; Galván-Blasco P; Fernández-Polo A; Cardona V; García-Palop B; Parramón-Teixidó CJ; Polverino E; Álvarez-Fernández A
    Front Pharmacol; 2024; 15():1392986. PubMed ID: 38933680
    [No Abstract]   [Full Text] [Related]  

  • 22. Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-Ivacaftor.
    Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
    medRxiv; 2023 Nov; ():. PubMed ID: 37645804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one
    Daines CL; Tullis E; Costa S; Linnemann RW; Mall MA; McKone EF; Polineni D; Quon BS; Ringshausen FC; Rowe SM; Selvadurai H; Taylor-Cousar JL; Withers NJ; Ahluwalia N; Moskowitz SM; Prieto-Centurion V; Tan YV; Tian S; Weinstock T; Xuan F; Zhang Y; Ramsey B; Griese M;
    Eur Respir J; 2023 Dec; 62(6):. PubMed ID: 37945033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real world outcomes of CFTR modulator therapy in Australian adults and children.
    Kuek S; McCullagh A; Paul E; Armstrong D
    Pulm Pharmacol Ther; 2023 Oct; 82():102247. PubMed ID: 37574040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome.
    Pallenberg ST; Pust MM; Rosenboom I; Hansen G; Wiehlmann L; Dittrich AM; Tümmler B
    Microbiol Spectr; 2022 Oct; 10(5):e0145422. PubMed ID: 36154176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients.
    Doligalski CT; McKinzie CJ; Yang A; Lobo LJ; Coakley R
    Pharmacotherapy; 2022 Jul; 42(7):580-584. PubMed ID: 35689451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.
    Sadras I; Kerem E; Livnat G; Sarouk I; Breuer O; Reiter J; Gileles-Hillel A; Inbar O; Cohen M; Gamliel A; Stanleigh N; Gunawardena T; Bartlett C; Gonska T; Moraes T; Eckford PDW; Bear CE; Ratjen F; Kerem B; Wilschanski M; Shteinberg M; Cohen-Cymberknoh M
    J Cyst Fibros; 2023 Nov; 22(6):1062-1069. PubMed ID: 37331863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cardiorespiratory Polygraphy Parameters and Respiratory Muscle Strength in Cystic Fibrosis Patients with Severe Lung Disease.
    Giallongo A; Parisi GF; Papale M; Manti S; Mulé E; Aloisio D; Terlizzi V; Rotolo N; Leonardi S
    Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalized medicine with drugs targeting the underlying protein defect in cystic fibrosis: is monitoring of treatment response necessary?
    Niedermayr K; Gasser V; Rueckes-Nilges C; Appelt D; Eder J; Fuchs T; Naehrlich L; Ellemunter H
    Ther Adv Chronic Dis; 2022; 13():20406223221108627. PubMed ID: 35959505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple Therapy for Cystic Fibrosis (Elexacaftor, Tezacaftor, and Ivacaftor): Desensitization After Skin Rash.
    Santos AI; Pacheco J; Cemlyn-Jones J; Gamboa F
    Cureus; 2023 Sep; 15(9):e46228. PubMed ID: 37905296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rescue of chloride and bicarbonate transport by elexacaftor-ivacaftor-tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers.
    Bijvelds MJC; Roos FJM; Meijsen KF; Roest HP; Verstegen MMA; Janssens HM; van der Laan LJW; de Jonge HR
    J Cyst Fibros; 2022 May; 21(3):537-543. PubMed ID: 34922851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis-An Observational Pilot Study.
    Korten I; Kieninger E; Krueger L; Bullo M; Flück CE; Latzin P; Casaulta C; Boettcher C
    Front Pediatr; 2022; 10():852551. PubMed ID: 35529332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy.
    Zaher A; ElSaygh J; Elsori D; ElSaygh H; Sanni A
    Cureus; 2021 Jul; 13(7):e16144. PubMed ID: 34268058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acneiform Eruption Following Elexacaftor-Tezacaftor-Ivacaftor Treatment in Patients With Cystic Fibrosis.
    Okroglic L; Sohier P; Martin C; Lheure C; Franck N; Honoré I; Kanaan R; Burgel PR; Carlotti A; Dupin N; Oulès B
    JAMA Dermatol; 2023 Jan; 159(1):68-72. PubMed ID: 36449298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. S945L-CFTR molecular dynamics, functional characterization and tezacaftor/ivacaftor efficacy
    Allan KM; Astore MA; Fawcett LK; Wong SL; Chen PC; Griffith R; Jaffe A; Kuyucak S; Waters SA
    Front Pediatr; 2022; 10():1062766. PubMed ID: 36467478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural changes in lung morphology detected by MRI after modulating therapy with elexacaftor/tezacaftor/ivacaftor in adolescent and adult patients with cystic fibrosis.
    Fainardi V; Skenderaj K; Ciuni A; Milanese G; Deolmi M; Longo F; Spaggiari C; Sverzellati N; Esposito S; Pisi G
    Respir Med; 2023 Sep; 216():107328. PubMed ID: 37321310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation.
    McKone EF; DiMango EA; Sutharsan S; Barto TL; Campbell D; Ahluwalia N; Higgins M; Owen CA; Tullis E
    J Cyst Fibros; 2021 Mar; 20(2):234-242. PubMed ID: 33339768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation.
    Roder L; Simonsen M; Fitzpatrick L; He J; Loucks J
    J Manag Care Spec Pharm; 2022 Sep; 28(9):989-996. PubMed ID: 36001103
    [No Abstract]   [Full Text] [Related]  

  • 39. Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis.
    Keens T; Hoffman V; Topuria I; Elder K; Cerf S; Mulder K; Roberts J; Lysinger J; Del Carmen Reyes M; Berdella M; Cairns AM; Jain M; Ganapathy V; Lou Y; Morcos B; Wu C; Sass L;
    Heliyon; 2024 Apr; 10(7):e28508. PubMed ID: 38586424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease.
    Terlizzi V; Colangelo C; Marsicovetere G; D'Andria M; Francalanci M; Innocenti D; Masi E; Avarello A; Taccetti G; Amato F; Comegna M; Castaldo G; Salvatore D
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.